Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Identifieur interne : 002098 ( PascalFrancis/Checkpoint ); précédent : 002097; suivant : 002099Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Auteurs : Andrew M. Wardley [Royaume-Uni, France, Mexique, Guatemala, Brésil, Costa Rica, Pologne, Suisse, Australie, Espagne] ; Xavier Pivot ; Flavia Morales-Vasquez ; Luis M. Zetina ; Maria De Fatima Dias Gaui ; Douglas Otero Reyes ; Jacek Jassem ; Claire Barton ; Peter Button ; Veronica Hersberger ; Antonio Anton TorresSource :
- Journal of clinical oncology [ 0732-183X ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. Patients and Methods Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m2 in HTX arm, 100 mg/m2 in HT arm, every 3 weeks) with or without X (950 mg/m2 twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR). Results In 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1 %) and grade 3/4 diarrhea (11 % v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm. Conclusion HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.
Affiliations:
- Australie, Brésil, Costa Rica, Espagne, France, Guatemala, Mexique, Pologne, Royaume-Uni, Suisse
- Angleterre, Bourgogne-Franche-Comté, Franche-Comté, Grand Manchester, État de Rio de Janeiro
- Besançon, Manchester, Rio de Janeiro
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0124645Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer</title>
<author><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>The Christie</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University Hospital of Besançon</s1>
<s2>Besançon</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto Nacional de Cancerología</s1>
<s2>Mexico City</s2>
<s3>MEX</s3>
</inist:fA14>
<country>Mexique</country>
<wicri:noRegion>Instituto Nacional de Cancerología</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hospital Roosevelt</s1>
<s2>Guatemala City</s2>
<s3>GTM</s3>
</inist:fA14>
<country>Guatemala</country>
<wicri:noRegion>Hospital Roosevelt</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Instituto Nacional do Câncer</s1>
<s2>Rio de Janeiro</s2>
<s3>BRA</s3>
</inist:fA14>
<country>Brésil</country>
<placeName><settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hospital Center for International Medicine Advanced</s1>
<s2>San José</s2>
<s3>CRI</s3>
</inist:fA14>
<country>Costa Rica</country>
<wicri:noRegion>Hospital Center for International Medicine Advanced</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Medical University of Gdansk</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>F. Hoffmann-La Roche Ltd</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Roche Products Pty Ltd</s1>
<s2>Dee Why, New South Wales</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Roche Products Pty Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hospital Universitario Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Universitario Miguel Servet</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
</author>
<author><name sortKey="Morales Vasquez, Flavia" sort="Morales Vasquez, Flavia" uniqKey="Morales Vasquez F" first="Flavia" last="Morales-Vasquez">Flavia Morales-Vasquez</name>
</author>
<author><name sortKey="Zetina, Luis M" sort="Zetina, Luis M" uniqKey="Zetina L" first="Luis M." last="Zetina">Luis M. Zetina</name>
</author>
<author><name sortKey="Dias Gaui, Maria De Fatima" sort="Dias Gaui, Maria De Fatima" uniqKey="Dias Gaui M" first="Maria De Fatima" last="Dias Gaui">Maria De Fatima Dias Gaui</name>
</author>
<author><name sortKey="Otero Reyes, Douglas" sort="Otero Reyes, Douglas" uniqKey="Otero Reyes D" first="Douglas" last="Otero Reyes">Douglas Otero Reyes</name>
</author>
<author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name>
</author>
<author><name sortKey="Barton, Claire" sort="Barton, Claire" uniqKey="Barton C" first="Claire" last="Barton">Claire Barton</name>
</author>
<author><name sortKey="Button, Peter" sort="Button, Peter" uniqKey="Button P" first="Peter" last="Button">Peter Button</name>
</author>
<author><name sortKey="Hersberger, Veronica" sort="Hersberger, Veronica" uniqKey="Hersberger V" first="Veronica" last="Hersberger">Veronica Hersberger</name>
</author>
<author><name sortKey="Anton Torres, Antonio" sort="Anton Torres, Antonio" uniqKey="Anton Torres A" first="Antonio" last="Anton Torres">Antonio Anton Torres</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0124645</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0124645 INIST</idno>
<idno type="RBID">Pascal:10-0124645</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002832</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003754</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002098</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002098</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer</title>
<author><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>The Christie</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University Hospital of Besançon</s1>
<s2>Besançon</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto Nacional de Cancerología</s1>
<s2>Mexico City</s2>
<s3>MEX</s3>
</inist:fA14>
<country>Mexique</country>
<wicri:noRegion>Instituto Nacional de Cancerología</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hospital Roosevelt</s1>
<s2>Guatemala City</s2>
<s3>GTM</s3>
</inist:fA14>
<country>Guatemala</country>
<wicri:noRegion>Hospital Roosevelt</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Instituto Nacional do Câncer</s1>
<s2>Rio de Janeiro</s2>
<s3>BRA</s3>
</inist:fA14>
<country>Brésil</country>
<placeName><settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hospital Center for International Medicine Advanced</s1>
<s2>San José</s2>
<s3>CRI</s3>
</inist:fA14>
<country>Costa Rica</country>
<wicri:noRegion>Hospital Center for International Medicine Advanced</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Medical University of Gdansk</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>F. Hoffmann-La Roche Ltd</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Roche Products Pty Ltd</s1>
<s2>Dee Why, New South Wales</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Roche Products Pty Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hospital Universitario Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Universitario Miguel Servet</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
</author>
<author><name sortKey="Morales Vasquez, Flavia" sort="Morales Vasquez, Flavia" uniqKey="Morales Vasquez F" first="Flavia" last="Morales-Vasquez">Flavia Morales-Vasquez</name>
</author>
<author><name sortKey="Zetina, Luis M" sort="Zetina, Luis M" uniqKey="Zetina L" first="Luis M." last="Zetina">Luis M. Zetina</name>
</author>
<author><name sortKey="Dias Gaui, Maria De Fatima" sort="Dias Gaui, Maria De Fatima" uniqKey="Dias Gaui M" first="Maria De Fatima" last="Dias Gaui">Maria De Fatima Dias Gaui</name>
</author>
<author><name sortKey="Otero Reyes, Douglas" sort="Otero Reyes, Douglas" uniqKey="Otero Reyes D" first="Douglas" last="Otero Reyes">Douglas Otero Reyes</name>
</author>
<author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name>
</author>
<author><name sortKey="Barton, Claire" sort="Barton, Claire" uniqKey="Barton C" first="Claire" last="Barton">Claire Barton</name>
</author>
<author><name sortKey="Button, Peter" sort="Button, Peter" uniqKey="Button P" first="Peter" last="Button">Peter Button</name>
</author>
<author><name sortKey="Hersberger, Veronica" sort="Hersberger, Veronica" uniqKey="Hersberger V" first="Veronica" last="Hersberger">Veronica Hersberger</name>
</author>
<author><name sortKey="Anton Torres, Antonio" sort="Anton Torres, Antonio" uniqKey="Anton Torres A" first="Antonio" last="Anton Torres">Antonio Anton Torres</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Breast cancer</term>
<term>C-Onc gene</term>
<term>Cancerology</term>
<term>Capecitabine</term>
<term>Clinical trial</term>
<term>Comparative study</term>
<term>Docetaxel</term>
<term>First line treatment</term>
<term>Human Epidermal growth factor Receptor 2</term>
<term>Metastasis</term>
<term>Phase II trial</term>
<term>Prodrug</term>
<term>Protooncogene</term>
<term>Randomization</term>
<term>Trastuzumab</term>
<term>erbB2 Gene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase II</term>
<term>Essai clinique</term>
<term>Randomisation</term>
<term>Docétaxel</term>
<term>Trastuzumab</term>
<term>Etude comparative</term>
<term>Traitement de première intention</term>
<term>Gène onc cellulaire</term>
<term>Protooncogène</term>
<term>Capécitabine</term>
<term>Gène erbB2</term>
<term>Stade avancé</term>
<term>Métastase</term>
<term>Cancer du sein</term>
<term>Cancérologie</term>
<term>Anticancéreux</term>
<term>Promédicament</term>
<term>Récepteur HER2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. Patients and Methods Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m<sup>2</sup>
in HTX arm, 100 mg/m<sup>2</sup>
in HT arm, every 3 weeks) with or without X (950 mg/m<sup>2</sup>
twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR). Results In 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1 %) and grade 3/4 diarrhea (11 % v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm. Conclusion HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>28</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WARDLEY (Andrew M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PIVOT (Xavier)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MORALES-VASQUEZ (Flavia)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ZETINA (Luis M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DIAS GAUI (Maria De Fatima)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>OTERO REYES (Douglas)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JASSEM (Jacek)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BARTON (Claire)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BUTTON (Peter)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>HERSBERGER (Veronica)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>ANTON TORRES (Antonio)</s1>
</fA11>
<fA14 i1="01"><s1>The Christie</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="02"><s1>University Hospital of Besançon</s1>
<s2>Besançon</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="03"><s1>Instituto Nacional de Cancerología</s1>
<s2>Mexico City</s2>
<s3>MEX</s3>
</fA14>
<fA14 i1="04"><s1>Hospital Roosevelt</s1>
<s2>Guatemala City</s2>
<s3>GTM</s3>
</fA14>
<fA14 i1="05"><s1>Instituto Nacional do Câncer</s1>
<s2>Rio de Janeiro</s2>
<s3>BRA</s3>
</fA14>
<fA14 i1="06"><s1>Hospital Center for International Medicine Advanced</s1>
<s2>San José</s2>
<s3>CRI</s3>
</fA14>
<fA14 i1="07"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
</fA14>
<fA14 i1="08"><s1>F. Hoffmann-La Roche Ltd</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</fA14>
<fA14 i1="09"><s1>Roche Products Pty Ltd</s1>
<s2>Dee Why, New South Wales</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="10"><s1>Hospital Universitario Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</fA14>
<fA20><s1>976-983</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000181407400140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0124645</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. Patients and Methods Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m<sup>2</sup>
in HTX arm, 100 mg/m<sup>2</sup>
in HT arm, every 3 weeks) with or without X (950 mg/m<sup>2</sup>
twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR). Results In 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1 %) and grade 3/4 diarrhea (11 % v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm. Conclusion HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Randomization</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Docétaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement de première intention</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>First line treatment</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento de primera línea</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Gène onc cellulaire</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>C-Onc gene</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Gen onc celular</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Protooncogène</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Protooncogene</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Protooncogen</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Capécitabine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Capecitabine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Capecitabina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Gène erbB2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>erbB2 Gene</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Gen erbB2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Métastase</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Metastasis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Metástasis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Promédicament</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Prodrug</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Promedicamento</s0>
<s5>26</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Récepteur HER2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Human Epidermal growth factor Receptor 2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Antimitotique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Antimitotic</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Antimitótico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Dérivé du taxane</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Taxane derivatives</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Taxane derivado</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Dérivé de la fluoropyrimidine</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Fluoropyrimidine derivatives</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Fluoropirimidina derivado</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pyrimidine nucléoside</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Pyrimidine nucleoside</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Pirimidina nucleósido</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Anti-HER2</s0>
<s4>INC</s4>
<s5>86</s5>
</fC07>
<fN21><s1>081</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Australie</li>
<li>Brésil</li>
<li>Costa Rica</li>
<li>Espagne</li>
<li>France</li>
<li>Guatemala</li>
<li>Mexique</li>
<li>Pologne</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Angleterre</li>
<li>Bourgogne-Franche-Comté</li>
<li>Franche-Comté</li>
<li>Grand Manchester</li>
<li>État de Rio de Janeiro</li>
</region>
<settlement><li>Besançon</li>
<li>Manchester</li>
<li>Rio de Janeiro</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Anton Torres, Antonio" sort="Anton Torres, Antonio" uniqKey="Anton Torres A" first="Antonio" last="Anton Torres">Antonio Anton Torres</name>
<name sortKey="Barton, Claire" sort="Barton, Claire" uniqKey="Barton C" first="Claire" last="Barton">Claire Barton</name>
<name sortKey="Button, Peter" sort="Button, Peter" uniqKey="Button P" first="Peter" last="Button">Peter Button</name>
<name sortKey="Dias Gaui, Maria De Fatima" sort="Dias Gaui, Maria De Fatima" uniqKey="Dias Gaui M" first="Maria De Fatima" last="Dias Gaui">Maria De Fatima Dias Gaui</name>
<name sortKey="Hersberger, Veronica" sort="Hersberger, Veronica" uniqKey="Hersberger V" first="Veronica" last="Hersberger">Veronica Hersberger</name>
<name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name>
<name sortKey="Morales Vasquez, Flavia" sort="Morales Vasquez, Flavia" uniqKey="Morales Vasquez F" first="Flavia" last="Morales-Vasquez">Flavia Morales-Vasquez</name>
<name sortKey="Otero Reyes, Douglas" sort="Otero Reyes, Douglas" uniqKey="Otero Reyes D" first="Douglas" last="Otero Reyes">Douglas Otero Reyes</name>
<name sortKey="Pivot, Xavier" sort="Pivot, Xavier" uniqKey="Pivot X" first="Xavier" last="Pivot">Xavier Pivot</name>
<name sortKey="Zetina, Luis M" sort="Zetina, Luis M" uniqKey="Zetina L" first="Luis M." last="Zetina">Luis M. Zetina</name>
</noCountry>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</region>
</country>
<country name="France"><region name="Bourgogne-Franche-Comté"><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</region>
</country>
<country name="Mexique"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Guatemala"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Brésil"><region name="État de Rio de Janeiro"><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</region>
</country>
<country name="Costa Rica"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Pologne"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
<country name="Espagne"><noRegion><name sortKey="Wardley, Andrew M" sort="Wardley, Andrew M" uniqKey="Wardley A" first="Andrew M." last="Wardley">Andrew M. Wardley</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002098 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 002098 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:10-0124645 |texte= Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer }}
This area was generated with Dilib version V0.6.33. |